{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:20Z","timestamp":1793640560545,"version":"4.5.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study was funded by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40257-026-01057-8","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:41:28Z","timestamp":1787042488000},"page":"1283-1295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct05536726","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ling","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsuo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zudong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiechi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9104-1294","authenticated-orcid":false,"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"publisher","first-page":"adv42945","DOI":"10.2340\/actadv.v105.42945","volume":"105","author":"C Skayem","year":"2025","unstructured":"Skayem C, Taieb C, Halioua B, et al. Epidemiology of psoriasis: a worldwide global study. Acta Derm Venereol. 2025;105:adv42945. https:\/\/doi.org\/10.2340\/actadv.v105.42945.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1057_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45. https:\/\/doi.org\/10.1038\/s41572-025-00630-5.","journal-title":"Nat Rev Dis Primers"},{"issue":"10281","key":"1057_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"19","key":"1057_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","volume":"10","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T. The role of IL-17 cytokines in psoriasis. Immunotargets Ther. 2021;10:409\u201318. https:\/\/doi.org\/10.2147\/ITT.S240891.","journal-title":"Immunotargets Ther."},{"issue":"9993","key":"1057_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8.","journal-title":"Lancet"},{"issue":"4","key":"1057_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"issue":"2","key":"1057_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386. https:\/\/doi.org\/10.1111\/bjd.14493.","journal-title":"Br J Dermatol"},{"issue":"10273","key":"1057_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(21)00126-4.","journal-title":"Lancet"},{"issue":"1","key":"1057_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai T-F, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.008.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1057_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomised, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358. https:\/\/doi.org\/10.1111\/bjd.19509.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1057_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6","volume":"7","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10201","key":"1057_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(19)31773-8.","journal-title":"Lancet"},{"issue":"1","key":"1057_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139. https:\/\/doi.org\/10.1111\/bjd.19341.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1057_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40257-025-00928-w","volume":"26","author":"D Kim","year":"2025","unstructured":"Kim D, Yang S, Gill M, Babaei N, Cervantes M, Wu JJ. Next-generation anti-IL-17 agents for psoriatic disease: a pipeline review. Am J Clin Dermatol. 2025;26(3):307\u201320. https:\/\/doi.org\/10.1007\/s40257-025-00928-w.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1057_CR16","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","volume":"14","author":"M Valenti","year":"2024","unstructured":"Valenti M, Gargiulo L, Ibba L, Malagoli P, Amoruso F, Balato A, et al. Long-term effectiveness and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenterretrospective study-IL PSO (Italian Landscape Psoriasis). Dermatol Ther. 2024;14(6):1649\u201357. https:\/\/doi.org\/10.1007\/s13555-024-01182-4.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1057_CR17","doi-asserted-by":"publisher","first-page":"e2024152","DOI":"10.5826\/dpc.1402a152","volume":"14","author":"G Caldarola","year":"2024","unstructured":"Caldarola G, Galluzzo M, Bernardini N, Botti E, De Luca E, De Simone C, et al. Long-term effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a real-life multicenter study of up to 3 years in a real-life Italian cohort. Dermatol Pract Concept. 2024;14(2):e2024152. https:\/\/doi.org\/10.5826\/dpc.1402a152.","journal-title":"Dermatol Pract Concept"},{"issue":"3","key":"1057_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.19682","volume":"38","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Burzi L, Rosset F, Giunipero di Corteranzo I, Leo F, et al. Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. J Eur Acad Dermatol Venereol. 2024;38(3):568\u201375. https:\/\/doi.org\/10.1111\/jdv.19682.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1057_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/ced\/llag021","volume":"51","author":"E De Luca","year":"2026","unstructured":"De Luca E, Dattola A, Artosi F, Bellinato F, Bianchi L, Burlando M, et al. Long-term effectiveness of bimekizumab in plaque psoriasis: two-year drug survival from a real-life multicenter Italian study. Clin Exp Dermatol. 2026;51(6):1028\u201333. https:\/\/doi.org\/10.1093\/ced\/llag021.","journal-title":"Clin Exp Dermatol"},{"issue":"13","key":"1057_CR20","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.3390\/jcm13133864","volume":"13","author":"M Galluzzo","year":"2024","unstructured":"Galluzzo M, Trovato E, Talamonti M, Caldarola G, Di Nardo L, Lazzeri L, et al. Long-term persistence rate of secukinumab in psoriatic patients: a six-year multicenter, real-world experience, retrospective study. J Clin Med. 2024;13(13):3864. https:\/\/doi.org\/10.3390\/jcm13133864.","journal-title":"J Clin Med"},{"issue":"12","key":"1057_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15929","volume":"35","author":"P Chicharro","year":"2022","unstructured":"Chicharro P, Llamas-Velasco M, Armesto S, Herrera Acosta E, Vidal D, Vilarrasa E, et al. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: multicenter study in 384 Spanish patients. Dermatol Ther. 2022;35(12):e15929. https:\/\/doi.org\/10.1111\/dth.15929.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1057_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1512711.","journal-title":"N Engl J Med"},{"issue":"1","key":"1057_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","volume":"92","author":"K Yan","year":"2025","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2025;92(1):92\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.031.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1057_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/bjd\/ljae062","volume":"191","author":"L Cai","year":"2024","unstructured":"Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, et al. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2024;191(3):336\u201343. https:\/\/doi.org\/10.1093\/bjd\/ljae062.","journal-title":"Br J Dermatol"},{"key":"1057_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","volume":"9","author":"BE Strober","year":"2019","unstructured":"Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019;9:5\u201318. https:\/\/doi.org\/10.1007\/s13555-018-0279-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1057_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/09546634.2020.1729335","volume":"33","author":"S Segaert","year":"2022","unstructured":"Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2022;33(1):111\u201320. https:\/\/doi.org\/10.1080\/09546634.2020.1729335.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1057_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","volume":"25","author":"F Bellinato","year":"2024","unstructured":"Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol. 2024;25(4):527\u201340. https:\/\/doi.org\/10.1007\/s40257-024-00857-0.","journal-title":"Am J Clin Dermatol"},{"issue":"21","key":"1057_CR28","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1610828","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102. https:\/\/doi.org\/10.1056\/NEJMc1610828.","journal-title":"N Engl J Med"},{"issue":"4","key":"1057_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/JD9.0000000000000244","volume":"5","author":"X Li","year":"2022","unstructured":"Li X, Zheng J, Pan W, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venereol. 2022;5(4):181\u201390. https:\/\/doi.org\/10.1097\/JD9.0000000000000244.","journal-title":"Int J Dermatol Venereol"},{"issue":"22","key":"1057_CR30","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020;133(22):2665\u201373. https:\/\/doi.org\/10.1097\/CM9.0000000000001163.","journal-title":"Chin Med J (Engl)"},{"key":"1057_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1810418","volume":"17","author":"L Cai","year":"2026","unstructured":"Cai L, Chen J, Wu L, Duan X, Zhang G, Li Y, et al. SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study. Front Immunol. 2026;17:1810418. https:\/\/doi.org\/10.3389\/fimmu.2026.1810418.","journal-title":"Front Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01057-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01057-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01057-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:31Z","timestamp":1793638951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01057-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01057-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jing Lou and Yanli Liu are employed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. The other authors have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with International Council for Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol was reviewed and approved by the relevant institutional review board or ethics committee at each study site. The lead site was Huashan Hospital, Fudan University, and the study was approved by the Ethics Committee of Huashan Hospital, Fudan University and the corresponding approval number is (2022) Clinical Trial Approval No. 928. Other information of ethics committees and the corresponding approval numbers are provided in the ESM.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent for participation.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data underlying this article will be made available upon request to the study sponsor.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: JX, JZ. Data acquisition: all authors contributed equally. Statistical analysis: all authors contributed equally. Funding acquisition: YL, JL. Investigation: all authors contributed equally. Methodology: JX, JZ, LH, HQ, XL. Project administration: JX, JZ. Resources: all authors contributed equally. Software: all authors contributed equally. Supervision: LH, HQ, XL. Validation: all authors contributed equally. Visualization: YL, JL. Writing original draft: LH, HQ, XL, YL, JL. Writing (review and editing): all authors contributed equally. All authors have read and approved the final version.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}